For healthcare professionals and procurement teams. This is editorial analysis, not patient advice, a product recommendation or a statement of South African availability.
Why it matters
A catheter that lets an electrophysiologist choose between two energy sources raises an important practical question: does procedural flexibility translate into outcomes that justify changing a service? This week's development is Abbott's 8 September announcement of US FDA approval for TactiFlex Duo, an ablation catheter combining pulsed field and radiofrequency energy. The announcement follows publication of the FlexPulse study in August. These are separate milestones: a new regulatory announcement and the earlier clinical evidence supporting it. [1,2]
For South African cardiology teams, the useful discussion starts with the actual study population, endpoint and follow-up. For procurement teams, it continues with the complete system required to deliver the procedure. Neither discussion is answered by the word “approved” alone.
What happened
Abbott says TactiFlex Duo can deliver pulsed field ablation, radiofrequency ablation or both during a procedure, with integration into its EnSite X mapping platform. The company attributes the US approval to FlexPulse results. This article reports that manufacturer announcement; it does not independently reproduce an FDA approval order or establish the exact approved US label. No South African registration, reimbursement decision, local launch or Aperture distribution relationship is asserted. [1]
The mechanism in brief
The device offers two energy options through one catheter rather than requiring the clinical team to treat every target in an identical way. Abbott describes the objective as creating lesions that interrupt abnormal electrical signals, with mapping supporting the identification and treatment of the relevant locations. That description explains the intended workflow; it does not establish that one energy choice is best for every patient. [1]
The data: keep the endpoints separate
FlexPulse was a prospective, multicentre, single-arm study of 180 patients with symptomatic, drug-refractory paroxysmal atrial fibrillation. Pulmonary vein isolation was achieved in all participants. The prespecified safety-event rate was 1.7%. The primary effectiveness endpoint was 74.6% at 12 months. That composite included recurrent atrial arrhythmia, repeat intervention, specified antiarrhythmic drug changes and cardioversion. [2]
Freedom from documented AF, atrial flutter or atrial tachycardia was 77.4%; the abstract also gives 92.6% when weekly transtelephonic monitoring was excluded. Those figures represent different assessments, not interchangeable estimates of success. Additional non-pulmonary-vein ablation occurred in 67 patients. A retrospective workflow analysis reported 84.6% freedom from those arrhythmias with specified PFA Index and lesion-spacing targets. It is an exploratory analysis, not a randomised comparison. [2]
What these numbers cannot decide
Our interpretation is that the first procurement slide should present the prespecified endpoint before any more favourable secondary or exploratory figure. A committee reading only a headline percentage could otherwise miss how success was defined or how actively recurrence was sought.
The difference between monitoring approaches deserves particular attention. When comparing a candidate platform with existing evidence, ask whether the studies used comparable surveillance, endpoint definitions and follow-up periods. A comparison assembled from attractive percentages across separate publications is not a substitute for a direct comparative trial.
Similarly, an immediate procedural result and a later clinical result answer different questions. A purchasing decision should not present them as equivalent. Ask the clinical lead to explain both in terms relevant to the proposed service, including which outcomes would be measured after adoption.
Expert perspective and the evidence boundary
Abbott's announcement quotes Atul Verma, Director of Cardiology at McGill University Health Centre, emphasising “greater flexibility during procedures”. That is a clearly attributed expert view within a manufacturer release, rather than an independent interview conducted for this journal. [1]
Our editorial test: establish the endpoint, the comparator and the local delivery requirements before turning a technology announcement into a purchasing conclusion. — Aperture Science Clinical Team.
This commentary checks the public study abstract and the dated announcement. It is not a complete manuscript, supplementary-data or regulatory-dossier review. We have not verified confidence intervals or patient-level subgroup data, and do not supply estimates that were unavailable in the reviewed material.
Implications for South African professional practice
The following is our proposed appraisal framework, not a recommendation to acquire or use this device. A local clinical and procurement team considering any new ablation platform could organise its review around four questions.
First, which service need is being addressed? Define the proposed patient group and explain how closely it matches the population in the supporting evidence. A broad description such as “complex cases” is insufficient to settle that question.
Second, what is the complete implementation proposal? Request a written account of required equipment, compatibility, consumables, training, service support and escalation arrangements. Compare a complete operating pathway with the existing pathway, rather than comparing catheter prices in isolation.
Third, what local permissions and funding arrangements actually apply? Obtain the relevant product documentation and written confirmation from the responsible parties. An overseas announcement should remain labelled overseas until the local position has been established.
Fourth, what would count as successful introduction? Agree in advance how the team would record procedure activity, repeat procedures, adverse events and follow-up completeness. This is a suggested governance approach, not a claim that the device already improves those measures locally.
What to watch next
The next useful evidence would clarify comparative performance, longer-term durability and implementation outside the original study. A complete review should examine the full protocol and supplementary material, including monitoring, event definitions and missing follow-up. Until then, the defensible conclusion is a new US regulatory milestone supported by single-arm clinical evidence, with local adoption questions still requiring their own answers.
Source material
